top of page
News
Apr 30, 2026
La Jolla Labs, Inc. Announces First Patient Treated with Custom Antisense Therapy GBFsen for familial ALS
Press release
Jan 12, 2026
La Jolla Labs Celebrates Advancing RNA Therapies for Patients as It Nears Five Years
Jun 18, 2025
La Jolla Labs featured in article about how a tailored ALS drug could help broaden rare disease therapies
"Beyond Ionis, the model is being pursued by various organizations, from the company La Jolla Labs to Boston Children's Hospital to the n-Lorem Foundation". La Jolla Labs is excited to continue our contribution to the N of 1 efforts, discovering therapeutics to rare diseases with unmet needs.
May 30, 2025
Co-Founder of La Jolla Labs', Jeff Milton, presents RNA Therapeutics: From Design to ASO Candidates, at the 2025 Mayo Clinic RNA Discoveries and Therapeutics Conference
La Jolla Labs' Co-Founder, Jeff Milton, will be presenting at the upcoming Mayo Clinic RNA Discoveries and Therapeutics Conference as a guest faculty speaker. His talk will be held Friday, May 30th from 2:30 - 3 pm and will cover the details of RNA therapeutics, from design to ASO candidates.
May 19, 2025
La Jolla Labs CEO, Tamar Grossman PhD, is attending TIDES USA: Oligonucleotide & Peptide Therapeutics 2025
La Jolla Labs CEO, Tamar Grossman PhD, is attending TIDES USA: Oligonucleotide & Peptide Therapeutics 2025
Feb 11, 2025
CTO of La Jolla Labs, Jeff Milton, Interviewed by Technology Networks for new Article: Tackling Rare Diseases With RNA Therapeutics
Learn how AI and automation can accelerate RNA drug discovery
Feb 5, 2025
La Jolla Labs, Inc. Announces Leadership Transition as Company Evolves from Technology to Therapeutics
La Jolla Labs Co-founder Tamar Grossman, Ph.D., formerly Global Head of Gene Therapy, RNA, and Delivery at Johnson & Johnson, will assume the position of Chief Executive Officer. Dr. Grossman brings extensive experience in RNA therapeutics and drug delivery, positioning the company for its next phase of growth in developing transformative treatments.
Oct 29, 2024
CEO of La Jolla Labs, Jeff Milton, presents at the Inaugural RNA and AI Symposium
Delve into the cutting-edge intersection of AI/machine learning and RNA biology and therapeutics and discover how AI/ML serves as an accelerant in advancing RNA research and therapeutic innovations.
Aug 15, 2024
Precision Medicine Working Group
The Precision Medicine Working Group explores cutting-edge RNA-targeting therapeutics using La Jolla Labs' software. Join a collaborative group of experts examining the many different methods to inform ASO & siRNA designs.
Aug 10, 2024
The 2024 Rose Gala and Precision Medicine Summit
CEO of La Jolla Labs, Jeff Milton, attends the Rose Gala and Precision Medicine Summit in Austin, Texas.
Feb 8, 2024
Chelsea's Hope Lafora Children Research Fund USA's Research Roundtable
CEO and Founder of La Jolla Labs, Jeff Milton, featured as a speaker in Chelsea's Hope Lafora Children Research Fund USA's Research Roundtable.
Feb 7, 2024
Expert Panelist at UCSF Invest In Cures Disease Foundation Forum 2024
Jeff Milton, the CEO and Founder of La Jolla Labs explores the synergy between AI and rare disease treatment as an expert panelist at UCSF Invest In Cures Disease Foundation Forum.
Sep 22, 2023
La Jolla Labs Mentioned in 1STRAND Article Titled: San Diego's RNA Cluster
La Jolla Labs partner, 1STRAND, quotes CEO of La Jolla Labs, Jeff Milton in article discussing San Diego's RNA cluster.
Aug 30, 2023
LJSplice (OpenAccess) is Released!
Our new ML models provide a roadmap for designing optimal splicing screens for antisense therapeutics.
Aug 24, 2023
Discussion Panelist at Invest in Cures San Diego 2023
La Jolla Labs CEO, Jeff Milton, joined the Innovation in Rare Disease Panel Discussion during LaunchBio's Invest In Cures Event to discuss how computational biology and machine learning may be used to address the unmet needs of rare disease patients.
Jul 27, 2023
La Jolla Labs Featured in Article about Rare Disease Drug Discovery.
"This is not a science problem anymore’: Paths emerge for scaling up rare disease medicine"(ENDPOINT NEWS).
Contact Us
bottom of page